Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13552MR)

This product GTTS-WQ13552MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13552MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2108MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ4812MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ8065MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ12551MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NV-01
GTTS-WQ11859MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ10039MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ3280MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ14400MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW